Silexion Therapeutics Corp
SLXN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.17
KIRA · Stoqly’s AI analyst, in plain words
- Silexion Therapeutics Corp lost $11.9M in fiscal 2025. From fiscal 2023 to 2025, diluted EPS grew −55.0% a year.
- Free cash flow was −$10.8M in fiscal 2025, — of revenue.
Market cap
$0.1M
P/E
—
Revenue
—
Net income
−$11.9M
Free cash flow
−$10.8M
Operating margin
—
Silexion Therapeutics Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$11.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Silexion Therapeutics Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Silexion Therapeutics Corp
- CIK
- 0002022416
Silexion Therapeutics Corp · SLXN
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$5.1M | −$16.5M | −$11.9M |
| Diluted EPS | $44.23 | $394.94 | $8.96 |
| Cash | |||
| Cash from operations | −$4.5M | −$8.4M | −$10.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$4.5M | −$8.4M | −$10.8M |
| Share count change | — | −62.8% | 3,095.9% |
| Debt and strength | |||
| Cash and short-term investments | $4.6M | $1.2M | $6.0M |
| Shareholders' equity | −$15.5M | −$4.0M | $2.6M |
| Current ratio | 2.3x | 0.6x | 2.4x |
| Returns and quality | |||
| Return on tangible equity | — | — | 457.6% |
| Altman Z'' | −26.3 | −82.3 | −31.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Silexion Therapeutics Corp · SLXN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.17 a share, the company is worth $0.1M.
Source: SEC EDGAR XBRL filings (CIK 0002022416). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.